Efficacy of nitric oxide, with or without continuing antihypertensive treatment, for management of high blood pressure in acute stroke (ENOS): a partial-factorial randomised controlled trial

• Published in: The Lancet (British edition) Vol. 385; no. 9968; pp. 617 - 628
• Main Authors: Bath, PMW, Woodhouse, L, Scutt, P, Krishnan, K, Wardlaw, JM, Bereczki, D, Sprigg, N, Berge, E, Beridze, M, Caso, V, Chen, C, Christensen, H, Collins, R, El Etribi, A, Laska, AC, Lees, KR, Ozturk, S, Phillips, S, Pocock, S, de Silva, HA, Szatmari, S, Utton, S
• Format: Journal Article
• Language: English
• Published: England Elsevier Ltd 14.02.2015; Elsevier Limited; Lancet Publishing Group
• Subjects: Aged; Aged, 80 and over; Antihypertensive Agents - therapeutic use; Blood pressure; Brain Ischemia - complications; Brain Ischemia - drug therapy; Cerebral Hemorrhage - complications; Cerebral Hemorrhage - drug therapy; Disease Management; Drug therapy; Drugs; Dysphagia; Female; Heart attacks; Humans; Hypertension; Internal Medicine; Male; Medical research; Medicin och hälsovetenskap; Middle Aged; Nitric oxide; Nitroglycerin - therapeutic use; Odds Ratio; Patients; Recovery of Function; Single-Blind Method; Stroke; Stroke - drug therapy; Stroke - etiology; Studies; Treatment Outcome; Vasodilator Agents - therapeutic use
• ISSN: 0140-6736; 1474-547X; 1474-547X
• DOI: 10.1016/S0140-6736(14)61121-1

Summary Background High blood pressure is associated with poor outcome after stroke. Whether blood pressure should be lowered early after stroke, and whether to continue or temporarily withdraw existing antihypertensive drugs, is not known. We assessed outcomes after stroke in patients given drugs to lower their blood pressure. Methods In our multicentre, partial-factorial trial, we randomly assigned patients admitted to hospital with an acute ischaemic or haemorrhagic stroke and raised systolic blood pressure (systolic 140–220 mm Hg) to 7 days of transdermal glyceryl trinitrate (5 mg per day), started within 48 h of stroke onset, or to no glyceryl trinitrate (control group). A subset of patients who were taking antihypertensive drugs before their stroke were also randomly assigned to continue or stop taking these drugs. The primary outcome was function, assessed with the modified Rankin Scale at 90 days by observers masked to treatment assignment. This study is registered, number ISRCTN99414122. Findings Between July 20, 2001, and Oct 14, 2013, we enrolled 4011 patients. Mean blood pressure was 167 (SD 19) mm Hg/90 (13) mm Hg at baseline (median 26 h [16–37] after stroke onset), and was significantly reduced on day 1 in 2000 patients allocated to glyceryl trinitrate compared with 2011 controls (difference −7·0 [95% CI −8·5 to −5·6] mm Hg/–3·5 [–4·4 to −2·6] mm Hg; both p<0·0001), and on day 7 in 1053 patients allocated to continue antihypertensive drugs compared with 1044 patients randomised to stop them (difference −9·5 [95% CI −11·8 to −7·2] mm Hg/–5·0 [–6·4 to −3·7] mm Hg; both p<0·0001). Functional outcome at day 90 did not differ in either treatment comparison—the adjusted common odds ratio (OR) for worse outcome with glyceryl trinitrate versus no glyceryl trinitrate was 1·01 (95% CI 0·91–1·13; p=0·83), and with continue versus stop antihypertensive drugs OR was 1·05 (0·90–1·22; p=0·55). Interpretation In patients with acute stroke and high blood pressure, transdermal glyceryl trinitrate lowered blood pressure and had acceptable safety but did not improve functional outcome. We show no evidence to support continuing prestroke antihypertensive drugs in patients in the first few days after acute stroke. Funding UK Medical Research Council.